CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)
Study sponsor: REGENXBIO Inc. · RGNX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-11-27Actual
Enrollment · participants48Estimated
Source updated2025-01-28Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.